Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLYS Mineralys Therapeutics, Inc.

Trading 02-24 15:41:26 EST

29.71

+0.78

+2.70%

High29.98	Low27.76	Vol564.55K
Open28.61	D1 Closing28.93	Amplitude7.67%
Mkt Cap2.35B	Tradable Cap1.66B	Total Shares79.14M
T/O16.55M	T/O Rate1.01%	Tradable Shares55.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":29.71,"timestamp":1771965683618,"preClose":28.93,"halted":0,"volume":564550,"delay":0,"changeRate":0.026961631524369208,"floatShares":55733200,"shares":79139956,"eps":-2.863576,"marketStatus":"Trading","change":0.78,"latestTime":"02-24 15:41:26 EST","open":28.61,"high":29.98,"low":27.7613,"amount":16552099.59865,"amplitude":0.076692,"askPrice":29.73,"askSize":126,"bidPrice":29.7,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.863576,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":28.93,"preHourTrading":{"tag":"盘前","latestPrice":28.48,"preClose":28.93,"latestTime":"09:24 EST","volume":798,"amount":22718.265192000003,"timestamp":1771943082762,"change":-0.45,"changeRate":-0.015555,"amplitude":0.050121},"postHourTrading":{"tag":"盘后","latestPrice":28.93,"preClose":28.93,"latestTime":"17:16 EST","volume":43673,"amount":1263459.89,"timestamp":1771884983153,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.596588,"impliedVol":1.2993,"impliedVolPercentile":0.9363},"requestUrl":"/m/hq/s/MLYS/wiki","defaultTab":"wiki","newsList":[{"id":"2612499799","title":"Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2612499799","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612499799?lang=en_us&edition=fundamental","pubTime":"2026-02-18 07:57","pubTimestamp":1771372629,"startTime":"0","endTime":"0","summary":"David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL4CZk0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2610960064","title":"Mineralys Therapeutics Grants Inducement Equity Awards to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610960064?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:00","pubTimestamp":1770854451,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Inc. has granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of its common stock to two new non-executive employees. The stock options will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date, February 9, 2026, and the remainder vesting in equal monthly installments thereafter. The restricted stock units will also vest over four years, with 25% vesting on each anniversary of the vesting commencement date. These awards were made under the company’s 2025 Employment Inducement Incentive Award Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLbJgBCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","MLYS","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","SG9999014005.SGD","BK4585","SG9999014039.USD","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2610960029","title":"Press Release: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960029","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610960029?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:00","pubTimestamp":1770854400,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Feb. 11, 2026  -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease , obstructive sleep apnea  and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys' Board of Directors granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of Mineralys common stock to two new non-executive employees.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4007","BK4139","LENZ","MLYS","BK4539"],"gpt_icon":0},{"id":"2610960068","title":"Chief Medical Officer David Malcom Rodman Sells Common Shares of Mineralys Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960068","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610960068?lang=en_us&edition=fundamental","pubTime":"2026-02-12 07:59","pubTimestamp":1770854366,"startTime":"0","endTime":"0","summary":"David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL7j2891:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Medical Officer David Malcom Rodman Sells Common Shares of Mineralys Therapeutics Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2605209407","title":"Mineralys Therapeutics Inc call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2605209407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605209407?lang=en_us&edition=fundamental","pubTime":"2026-01-24 02:25","pubTimestamp":1769192713,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Mineralys Therapeutics (MLYS) Inc with 1,300 calls trading, 3x expected, and implied vol increasing almost 6 points...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-inc-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mineralys-therapeutics-inc-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","MLYS","BK4539","BK4007"],"gpt_icon":0},{"id":"2605257171","title":"Chief Medical Officer David Malcom Rodman Reports Sale of Mineralys Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605257171","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605257171?lang=en_us&edition=fundamental","pubTime":"2026-01-21 09:34","pubTimestamp":1768959263,"startTime":"0","endTime":"0","summary":"David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics Inc., reported a disposal of common shares of Mineralys Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL43lDGn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Medical Officer David Malcom Rodman Reports Sale of Mineralys Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2604904326","title":"Mineralys Therapeutics (MLYS) Valuation After Q3 Beat And Lorundrostat NDA Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2604904326","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604904326?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:26","pubTimestamp":1768782367,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics (MLYS) is back in focus after reporting third quarter 2025 earnings that surpassed expectations, updating investors on lorundrostat’s path toward a New Drug Application and expanding its clinical program.\nSee our latest analysis for Mineralys Therapeutics.\nThe latest updates on lorundrostat and Q3 2025 results come after a mixed year in the market, with a 1 day share price return of 4.33% to US$32.74, a 90 day share price return decline of 25.86%, and a 1 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/mineralys-therapeutics-mlys-valuation-after-q3-beat-and-loru","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/mineralys-therapeutics-mlys-valuation-after-q3-beat-and-loru","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MLYS","PRGS","BK4139","DCF","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2603652774","title":"Mineralys Therapeutics CEO Jon Congleton Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603652774","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603652774?lang=en_us&edition=fundamental","pubTime":"2026-01-14 09:44","pubTimestamp":1768355064,"startTime":"0","endTime":"0","summary":"Jon Congleton, Chief Executive Officer of Mineralys Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL4Y96pm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Therapeutics CEO Jon Congleton Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2603965277","title":"CFO Adam Scott Levy Sells Common Shares of Mineralys Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2603965277","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603965277?lang=en_us&edition=fundamental","pubTime":"2026-01-14 09:44","pubTimestamp":1768355055,"startTime":"0","endTime":"0","summary":"Adam Scott Levy, Chief Financial Officer and Secretary of Mineralys Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDLc4ZxV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2603636782","title":"Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2603636782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603636782?lang=en_us&edition=fundamental","pubTime":"2026-01-14 00:30","pubTimestamp":1768321847,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. ($MLYS) announced an update on their ongoing clinical study. Mineralys Therapeutics (MLYS) has completed a Phase 2 stu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mineralys-targets-sleep-apnea-and-hypertension-with-lorundrostat-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mineralys-targets-sleep-apnea-and-hypertension-with-lorundrostat-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLYS","BK4211","ISBC"],"gpt_icon":0},{"id":"2601974298","title":"Mineralys Therapeutics Inc - Filed Nda for Lorundrostat to U.S. FDA in Late 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2601974298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601974298?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:12","pubTimestamp":1767705165,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70CG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2601889747","title":"Mineralys Therapeutics Inc - Co Remains on Track to Report Topline Results From Phase 2 Explore-Osa Trial in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889747?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:12","pubTimestamp":1767705165,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70CG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2601897664","title":"Mineralys Therapeutics Submits NDA for Lorundrostat to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897664","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897664?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:01","pubTimestamp":1767704494,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Inc. has filed a New Drug Application  with the U.S. Food and Drug Administration  for lorundrostat, following the successful completion of three positive clinical trials in 2025. The NDA submission marks a key regulatory milestone for the company as it seeks approval for lorundrostat, a drug candidate designed to treat hypertension and related comorbidities. The NDA is supported by data demonstrating lorundrostat’s safety, 24-hour blood pressure control, and efficacy across diverse patient populations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely responsible for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL6VVtrJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","SG9999014039.USD","LU2210149790.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4588","BK4139","IE00B3QW5Z07.USD","MLYS","IE00BKPKM429.USD","BK4585","LU0314104364.USD","SG9999014005.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2593428124","title":"Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593428124","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593428124?lang=en_us&edition=fundamental","pubTime":"2025-12-21 17:14","pubTimestamp":1766308473,"startTime":"0","endTime":"0","summary":"In December 2025, Mineralys Therapeutics reported that its Phase 3 Launch-HTN trial of lorundrostat for uncontrolled or treatment-resistant hypertension was featured in JAMA’s inaugural “Research of the Year Roundup” as one of the most impactful studies of the year.\nThis recognition, framed by JAMA as “New Hope for Treatment-Resistant Hypertension,” highlights both the growing clinical interest in aldosterone as a therapeutic target and the breadth of lorundrostat data across four completed...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/did-jamas-research-of-the-year-spotlight-on-lorundrostat-jus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/did-jamas-research-of-the-year-spotlight-on-lorundrostat-jus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2592166156","title":"Mineralys Therapeutics Inc : Bofa Global Research Raises Price Objective to $46 From $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166156?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:29","pubTimestamp":1766143793,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XP0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2588722794","title":"How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722794","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722794?lang=en_us&edition=fundamental","pubTime":"2025-12-01 17:16","pubTimestamp":1764580578,"startTime":"0","endTime":"0","summary":"In recent news, Findell Capital Management initiated a new US$9.5 million position in Mineralys Therapeutics after the company completed an upsized US$287.5 million capital offering to support ongoing clinical development of lorundrostat for resistant hypertension.\nThis influx of institutional investment reflects increased confidence in Mineralys' financial strength and its progress in advancing pivotal research programs.\nWe'll explore how Mineralys' expanded cash reserves are shaping its...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/how-investors-may-respond-to-mineralys-therapeutics-mlys-aft","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/how-investors-may-respond-to-mineralys-therapeutics-mlys-aft","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","MLYS","ISBC","BK4139"],"gpt_icon":0},{"id":"2586497260","title":"BRIEF-Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586497260","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586497260?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:13","pubTimestamp":1764191608,"startTime":"0","endTime":"0","summary":"BRIEF-Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)Nov 26 (Reuters) - Mineralys Therapeutics Inc MLYS.O:MINERALYS THERAPEUTICS REPORTS INDUCEMENT AWARD UNDER NAS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA62TJT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2585217551","title":"Director and 10% Owner Brian Taylor Slingsby Reports Disposal of Mineralys Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585217551","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585217551?lang=en_us&edition=fundamental","pubTime":"2025-11-22 07:08","pubTimestamp":1763766520,"startTime":"0","endTime":"0","summary":"Brian Taylor Slingsby, a Director and 10% Owner, reported a disposal of common shares of Mineralys Therapeutics Inc. The filing was made by more than one reporting person, including Slingsby and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL5GBThC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director and 10% Owner Brian Taylor Slingsby Reports Disposal of Mineralys Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2584921969","title":"Mineralys Therapeutics Q3 EPS USD -0.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2584921969","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584921969?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:15","pubTimestamp":1763572541,"startTime":"0","endTime":"0","summary":"Nov 10 (Reuters) - Mineralys Therapeutics Q3 operating expenses USD 41.131 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 10-NOV-202521:05:47.98 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6PYypb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2583819683","title":"Mineralys Therapeutics Shares Fall Following Executives' Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2583819683","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583819683?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:57","pubTimestamp":1763139456,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics (MLYS) shares were down more than 10% in recent Friday trading following a series of stock sales by a number of company executives.Filings with the US Securities and Exchange Co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","MLYS","BK4139","LENZ","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com","stockEarnings":[{"period":"1week","weight":0.0482},{"period":"1month","weight":-0.1174},{"period":"3month","weight":-0.3145},{"period":"6month","weight":0.902},{"period":"1year","weight":2.0262},{"period":"ytd","weight":-0.2028}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014493},{"month":2,"riseRate":0.333333,"avgChangeRate":0.077881},{"month":3,"riseRate":0.333333,"avgChangeRate":0.152528},{"month":4,"riseRate":0,"avgChangeRate":-0.099137},{"month":5,"riseRate":1,"avgChangeRate":0.0733},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.014247},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.022154},{"month":8,"riseRate":0.666667,"avgChangeRate":0.001437},{"month":9,"riseRate":0.333333,"avgChangeRate":0.388697},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.001589},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.0429},{"month":12,"riseRate":0.333333,"avgChangeRate":0.032291}],"exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction